Today: 9 June 2026
BitMine Immersion (BMNR) stock jumps 15% as Tom Lee pushes 50-billion share authorization vote
4 January 2026
2 mins read

BitMine Immersion (BMNR) stock jumps 15% as Tom Lee pushes 50-billion share authorization vote

NEW YORK, January 4, 2026, 06:51 ET — Market closed

  • BitMine Immersion shares closed up 14.9% on Friday after the company urged holders to back a large increase in authorized shares.
  • The proposal would raise the share cap to 50 billion from 500 million, a filing showed.
  • Investors are watching the Jan. 14 voting deadline and any follow-on capital-raising plans.

BitMine Immersion Technologies Inc shares closed sharply higher in the last U.S. session after the crypto-focused company stepped up its push for shareholders to approve a sweeping increase in its authorized shares. The stock ended Friday up 14.9% at $31.19.

The vote matters because authorized shares set the maximum number of shares a company is allowed to issue under its charter. Raising that ceiling can give management room for stock sales, stock-based deals or stock splits, but it can also amplify dilution worries if new shares are issued.

BitMine’s voting deadline is January 14, and the annual meeting is set for January 15, putting the proposal on a near-term clock. The company has positioned its stock as closely linked to ether, the world’s second-largest cryptocurrency, making any move that touches share count and trading mechanics a focal point for retail and momentum investors.

In a regulatory filing dated Friday, BitMine said it issued a press release encouraging shareholders to vote “FOR” a charter amendment proposal at the upcoming meeting. Sec

The amendment would lift the number of authorized shares to 50 billion from 500 million, according to the filing materials. Authorized shares are not the same as shares outstanding — a company can raise its authorized share count without immediately issuing stock — but the change would expand the company’s capacity to do so.

Chairman Tom Lee framed the proposal primarily as a way to enable future stock splits, which increase the number of shares while lowering the per-share price. “Bitmine’s stock price follows the price of Ethereum,” Lee said in a transcript filed with the SEC. Sec

Lee also pointed to the need for flexibility around capital markets activity and potential acquisitions, according to the transcript. An at-the-market offering, one tool he cited, is a program that allows a company to sell shares into the market over time rather than in one large deal.

BitMine describes itself as a Bitcoin and Ethereum “network company” focused on accumulating crypto for long-term investment, including through mining and capital-raising proceeds, the press release said. It said its operations are located in “low-cost energy regions” including Trinidad and two Texas sites.

The next leg for the shares may hinge as much on macro risk appetite as on company-specific filings. Philadelphia Fed President Anna Paulson said on Saturday that further U.S. interest-rate cuts could take time as policymakers evaluate the economy, according to Reuters — commentary that can sway high-volatility corners of the market, including crypto-linked equities.

Before the next session, investors will be looking to the week’s U.S. data calendar for clues on rates and risk sentiment. The Labor Department is scheduled to release the December employment report on January 9 and the December CPI report on January 13.

Company-specific, the key date remains the January 14 voting deadline ahead of the January 15 annual meeting. Traders will also be alert for any new disclosures about capital-raising plans or an eventual stock split once the vote outcome is known. The Fed’s next policy meeting is scheduled for January 27–28.

Stock Market Today

  • Constant and Constant Advises Piraeus Bank on Safe Bulkers Euronext Athens Dual Listing
    June 9, 2026, 9:51 AM EDT. Constant and Constant Greece and UK firm TLT advised Piraeus Bank on the dual listing of Safe Bulkers, Inc. on Euronext Athens, marking the first Greek shipping company listed in New York to also trade on Athens' exchange. Safe Bulkers, a marine dry bulk carrier with 45 vessels, is now accessible to both U.S. and Greek investors. The legal teams led cross-border due diligence covering loan facilities, guarantees, and fleet agreements to ensure compliance. This move is expected to pave the way for similar listings, enhancing Greece's capital markets. Safe Bulkers' CFO praised the firms for precise, detailed legal support throughout the complex process.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals
Previous Story

RIOT stock jumps after Riot Platforms names new CFO and ties bonuses to data-center deals

Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Next Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Go toTop